“…In this study, we evaluated whether administration of MS-275 (also known as entinostat), a selective inhibitor of class 1 histone deacetylases (HDACs), counteracts the development of pancreatic fibrosis using the widespread murine model of cerulein-induced chronic pancreatitis. The rationale for this approach was 3-fold: 1) development of fibrosis activates a substantial gene regulation, which is prominently orchestrated by epigenetic mechanisms (McDonnell et al, 2014;Weigel et al, 2015;Yang and Schwartz, 2015;Moran-Salvador and Mann, 2017); 2) HDACs are critical epigenetic regulators, and expression of class 1 HDACs is significantly upregulated during the course of chronic pancreatitis (Bombardo et al, 2017); and 3) pharmacologic inhibitors of HDAC activity, originally developed as anticancer agents, are currently being investigated for their antifibrotic properties in different fibrotic diseases (recently reviewed in Pang and Zhuang, 2010;Royce et al, 2014;Chen et al, 2015;Schuetze et al, 2016).…”